{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male&page=5",
    "query": {
      "condition": "Male",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 12734,
    "total_pages": 1274,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Male&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T04:28:09.276Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04688931",
      "title": "A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-102",
          "type": "DRUG"
        },
        {
          "name": "TURBT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2021-02-19",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04688931"
    },
    {
      "nct_id": "NCT05544955",
      "title": "Protein Ingestion Timing on Body Composition and Biochemical Markers in Resistance-trained Males",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertrophy",
        "Physical Performance"
      ],
      "interventions": [
        {
          "name": "isolate whey protein prior to and immediately after resistance training",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "isolate whey protein 3 hours prior to and 3 hours after resistance training",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Marymount University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2022-09-17",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Arlington, Virginia",
      "locations": [
        {
          "city": "Arlington",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544955"
    },
    {
      "nct_id": "NCT00492596",
      "title": "The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Incontinence, Stress"
      ],
      "interventions": [
        {
          "name": "AttenueX IntraVesical System",
          "type": "DEVICE"
        },
        {
          "name": "Sham Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Solace Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 166,
      "start_date": "2006-06",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-11",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Downey, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492596"
    },
    {
      "nct_id": "NCT01652794",
      "title": "Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leydig Cell Tumor",
        "Ovarian Sarcoma",
        "Ovarian Stromal Cancer",
        "Pseudomyxoma Peritonei",
        "Recurrent Cervical Cancer",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Primary Peritoneal Cavity Cancer",
        "Recurrent Uterine Sarcoma",
        "Recurrent Vaginal Cancer",
        "Recurrent Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "stereotactic body radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacogenomic studies",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2012-05",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-08-04",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652794"
    },
    {
      "nct_id": "NCT00586131",
      "title": "Arterial pH and Total Body Nitrogen Balances in APD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End-stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "ammonium chloride or sodium citrate/citric acid",
          "type": "DRUG"
        },
        {
          "name": "Sodium citrate/citratic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2003-09",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2017-09-05",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586131"
    },
    {
      "nct_id": "NCT03964337",
      "title": "Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostate Cancer Adenocarcinoma",
        "Non-Metastatic"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2020-03-17",
      "completion_date": "2021-06-04",
      "has_results": true,
      "last_update_posted_date": "2022-06-29",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03964337"
    },
    {
      "nct_id": "NCT03497377",
      "title": "Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "18F-DCFPyL Injection",
          "type": "DRUG"
        },
        {
          "name": "18F-NaF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2016-05-16",
      "completion_date": "2020-04",
      "has_results": false,
      "last_update_posted_date": "2020-05-07",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03497377"
    },
    {
      "nct_id": "NCT04848519",
      "title": "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Bladder Urothelial Carcinoma",
        "Locally Advanced Renal Pelvis Urothelial Carcinoma",
        "Locally Advanced Ureter Urothelial Carcinoma",
        "Locally Advanced Urethral Urothelial Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Renal Pelvis Urothelial Carcinoma",
        "Metastatic Ureter Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Renal Pelvis Cancer AJCC v8",
        "Stage IV Ureter Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Propranolol Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-05-20",
      "completion_date": "2026-12-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04848519"
    },
    {
      "nct_id": "NCT02626130",
      "title": "Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Cancer",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cryosurgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-03-30",
      "completion_date": "2022-06-20",
      "has_results": false,
      "last_update_posted_date": "2022-07-07",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02626130"
    },
    {
      "nct_id": "NCT00003930",
      "title": "Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "1999-09",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-10-21T04:28:09.276Z",
      "location_count": 210,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003930"
    }
  ]
}